Psoriatic arthritis (PsA) is classified as a spondylarthropathy based on its clinical and serological characteristics. The clinical manifestations and the association with psoriasis or nail psoriasis have led, together with immunological characteristics, to a further differentiation. The pathophysiological and genetic understanding of this disease has advanced as a result of the development of new treatment strategies and targets in rheumatology and dermatology. Collaborative efforts and increasing multidisciplinary cooperation between rheumatologists and dermatologists have led to an increased awareness in early diagnosis and treatment. New treatment modalities have demonstrated significant efficacy in preventing radiologic progression resulting in amelioration of clinical symptoms, improvement of function and quality of life.